Published: 24 November 2025

Zimbabwe has cleared the use of Lenacapavir, a long-acting injectable medicine for HIV pre-exposure prophylaxis (PrEP), marking a major advancement in the country's HIV prevention efforts. The Medicines Control Authority of Zimbabwe (MCAZ) announced on Saturday that the drug received approval after an expedited 23-day review, reflecting its potential public health impact.

Lenacapavir, developed by Gilead, is administered only twice a year, offering an alternative to daily oral PrEP, which some users find difficult to adhere to. The drug is approved for adults and adolescents weighing at least 35 kilograms who are HIV-negative and at substantial risk of infection. Its administration involves a six-monthly subcutaneous injection following an initial phase that combines one injection with oral tablets taken on the first two days.

MCAZ emphasised that Lenacapavir should be used alongside safer sex practices, including condom use and other behavioural risk-reduction measures.

Director-General of MCAZ, Richard Rukwata, hailed the rapid approval as a demonstration of the authority's commitment to expanding access to life-saving health tools. "The rapid approval of Lenacapavir reflects MCAZ's dedication to accelerating access to trusted, high-quality health products," he said. "This milestone brings new hope for HIV prevention and reinforces our commitment to safeguarding public health."

The approval is expected to provide a more convenient and effective option for individuals at high risk of HIV infection, potentially reducing new cases and improving adherence to preventive treatment.
- The Herald

You might also want to read this

• Bulawayo records major drop in HIV prevalence
• HIV experiment rollout in Zimbabwe sparks debate
• Experimental HIV/ Aids jab hits Zimbabwe
• Mnangagwa urged to open HIV centre in South Africa
• Zimbabwe steps up domestic HIV/Aids funding drive
• Zimbabwe launches 'HIV prevention' pill
• Zimbabwe defers HIV drug roll out
• Zimbabwe scores another HIV first
• Drug-resistant HIV worries Government